MORGAN STANLEY PLC/CALL/EDWARDS LIFESCIENCES/120/0.1/19.12.25 | Real-time Bid/Ask 10:18:12 2024-06-07 EDT | ||
| 0.73 EUR / 0.74 EUR | +2.08% |
|
| Current month | +14.29% | ||
| 1 month | +41.18% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about EDWARDS LIFESCIENCES CORPORATION
More news
| Date | Price | Change |
|---|---|---|
| 24-06-07 | 0.7 | -2.78% |
| 24-06-06 | 0.72 | 0.00% |
| 24-06-05 | 0.72 | +7.46% |
| 24-06-04 | 0.67 | -1.47% |
| 24-06-03 | 0.68 | +7.94% |
Delayed Quote Börse Stuttgart
Last update June 07, 2024 at 09:14 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | EDWARDS LIFESCIENCES CORPORATION |
| Issuer | Morgan Stanley |
| WKN | MB9D26 |
| ISIN | DE000MB9D264 |
| Date issued | 2023-08-01 |
| Strike | 120 $ |
| Maturity | 2025-12-19 (560 Days) |
| Parity | 10 : 1 |
| Emission price | 0.66 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.99 € |
|---|---|
| Lowest since issue | 0.31 € |
| Spread | 0.01 € |
| Spread % | 1.35% |
Company Profile
Edwards Lifesciences Corporation specializes in designing, manufacturing and marketing medical systems and devices for treating cardiovascular diseases. Net sales break down by family of products as follows:
- heart valves and surgery products (67.9%);
- hemodynamic monitoring systems (15.5%);
- other (16.6%): balloon catheters, artificial implants, etc.
Net sales are distributed geographically as follows: the United States (58.4%), Europe (22.2%), Japan (7.6%) and other (11.8%).
Sector
-
Ratings for Edwards Lifesciences Corporation
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Edwards Lifesciences Corporation
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
87.68
USD
Average target price
96.31
USD
Spread / Average Target
+9.84%
- Stock Market
- Warrants
- Warrant
